Join to View Full Profile
3181 Sw Sam Jackson Park RdPortland, OR 97239
Phone+1 503-494-6346
Fax+1 608-266-6020
Dr. Cetnar is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2006 - 2009
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2002 - 2005
Loyola University Chicago Stritch School of MedicineClass of 2002
Certifications & Licensure
OR State Medical License 2013 - 2027
WI State Medical License 2009 - 2013
PA State Medical License 2006 - 2010
MN State Medical License 2005 - 2006
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification PRISM, IOD Incorporated, 2012-2014, 2016-2017
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
- Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Publications & Presentations
PubMed
- Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line o...Isamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, Jonathan W Goldman, Adrianus J de Langen
Lung Cancer. 2026-08-01 - Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated SCLC: A Case Report.Ryan Cheng, Sarah Reddy, Kendra Gee-Rodriguez, Rogelyn Harlan, Chetan Vakkalagadda
JTO Clinical and Research Reports. 2026-06-01 - Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.Raymond U Osarogiagbon, Jeremy P Cetnar, Raid Aljumaily
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2026-06-01
Press Mentions
Stronger Rules Needed for Oncology Financial Conflicts of Interest, Critics ArgueMay 2nd, 2024- Gemcitabine, Cisplatin, plus Nivolumab in Patients with Muscle-Invasive Bladder Cancer with Selective Bladder SparingJune 15th, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
